Melatonin relieves diabetic complications and regenerates pancreatic beta cells by the reduction in NF-kB expression in streptozotocin induced diabetic rats Melatonin: anti-diabetic drug

dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorFarid, Alyaa
dc.contributor.authorMoussa, Passant
dc.contributor.authorYoussef, Manar
dc.contributor.authorHaytham, Merna
dc.contributor.authorShamy, Ali
dc.contributor.authorSafwat, Gehan
dc.date.accessioned2022-05-25T06:23:41Z
dc.date.available2022-05-25T06:23:41Z
dc.date.issued22/05/2022
dc.descriptionSJR : Scientific Journal Rankings - Scimago https://bit.ly/3lTxpg9
dc.descriptionhttps://bit.ly/3lTxpg9
dc.description.abstractMelatonin, a pleiotropic hormone, has many regulatory effects on the circadian and seasonal rhythms, sleep and body immune system. It is used in the treatment of blind circadian rhythm sleep disorders, delayed sleep phase and insomnia. It is a potent antioxidant, anti-inflammatory, free radical scavenger, helpful in fighting infectious disease and cancer treatment. Decreased level of circulating melatonin was associated with an increased blood glucose level, losing the anti-oxidant protection and anti-inflammatory responses. We aimed to evaluate the effect of melatonin administration, in streptozotocin (STZ) induced diabetic rats, on blood glucose level and pancreatic beta (β) cells. Diabetes mellitus was induced in Sprague dawley male rats by the intravenous (i.v) injection of 65 mg/kg of STZ. Diabetic rats received melatonin at a dose of 10 mg/kg daily for 8 weeks by oral routes. The results showed, after 8 weeks of melatonin administration, a reduction in: 1- fasting blood glucose (FBG) and fructosamine (FTA) levels, 2- kidney and liver function parameters, 3- levels of serum triglycerides, cholesterol and LDL-C, 4- malondialdehyde (MDA), 5- NF-κB expression in treated group, 6- pro-inflammatory cytokines (IL-1β and IL-12) and immunoglobulin (IgA, IgE and IgG). Furthermore, an elevation in insulin secretion was noticed in melatonin treated group that indicated beta cells regeneration. Therefore, melatonin administration, in STZ induced diabetic rats; reduced hyperglycemia, hyperlipidemia and oxidative stress. Melatonin acted as an anti-inflammatory agent that reduced pro-inflammatory cytokines (IL-1β and IL-12) and oxidative stress biomarkers (MDA). Melatonin succeeded in protecting β cells under severe inflammatory situations, which was apparent by the regeneration of islets of Langerhans in treated diabetic rats. Moreover, these results can open a gate for diabetes management and treatment.en_US
dc.description.urihttps://bit.ly/3x5kFto
dc.identifier.doihttps://doi.org/10.1016/j.sjbs.2022.103313
dc.identifier.otherhttps://doi.org/10.1016/j.sjbs.2022.103313
dc.identifier.urihttp://repository.msa.edu.eg/xmlui/handle/123456789/4953
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.relation.ispartofseriesSaudi Journal of Biological Sciences;
dc.subjectβ-cellsen_US
dc.subjectDiabetes mellitusen_US
dc.subjectIL-1βen_US
dc.subjectIL-12en_US
dc.subjectinflammationen_US
dc.titleMelatonin relieves diabetic complications and regenerates pancreatic beta cells by the reduction in NF-kB expression in streptozotocin induced diabetic rats Melatonin: anti-diabetic drugen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2.0-S1319562X22002297-main.pdf
Size:
3.47 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
51 B
Format:
Item-specific license agreed upon to submission
Description: